Meet The Top 12 CEOs In The Psychedelics Industry
By Natan Ponieman and Javier Hasse
The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate leaders, working to create new methods for the treatment of mental health and other serious conditions.
ATAI Life Sciences Shares See Volume; Traders Circulate TipRanks Report Titled ‘Billionaire Israel Englander Pours Money Into 3 “Strong Buy” Stocks’ Mentioning Stock
https://www.tipranks.com/news/article/billionaire-israel-englander-pours-money-into-3-strong-buy-stocks/
What 10 Analyst Ratings Have To Say About ATAI Life Sciences
Analysts have provided the following ratings for ATAI Life Sciences (NASDAQ:ATAI) within the last quarter:
Where ATAI Life Sciences Stands With Analysts
ATAI Life Sciences (NASDAQ:ATAI) has observed the following analyst ratings within the last quarter:
Last 30 Days
1 Month Ago
2 Months Ago
What 9 Analyst Ratings Have To Say About ATAI Life Sciences
ATAI Life Sciences (NASDAQ:ATAI) has observed the following analyst ratings within the last quarter:
Last 30 Days
1 Month Ago
2 Months Ago
Argus Research Maintains Buy on ATAI Life Sciences, Raises Price Target to $27
Argus Research analyst Nathan Weinstein maintains ATAI Life Sciences (NASDAQ:ATAI) with a Buy and raises the price target from $26 to $27.
Aegis Capital Maintains Buy on ATAI Life Sciences, Raises Price Target to $27
Aegis Capital analyst Nathan Weinstein maintains ATAI Life Sciences (NASDAQ:ATAI) with a Buy and raises the price target from $26 to $27.
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 16)